

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
020018-C2-03-DCL

In Re Application Of: Dennis Nelson and Craig Sheehan

Serial No.	Filing Date	Examiner	Group Art Unit
10/719,555	11/21/2003	Not yet assigned	1614

Title: CYCLODEXTRINS IN DENTAL PRODUCTS

Address to:

Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
 - the statement specified in 37 CFR 1.97(e);

OR
 - the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
020018-C2-03-DCL

In Re Application: Dennis Nelson and Craig Sheehan

Serial No.

10/719,555

Filing Date

11/21/2003

Examiner

Not yet assigned

Group Art Unit

1614

CYCLODEXTRINS IN DENTAL PRODUCTS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 23-0458 as described below. A duplicate copy of this sheet is enclosed.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Darryl C. Little, Reg. No. 40,703

Pfizer Inc.

201 Tabor Road

Morris Plains, NJ 07950

Phone: 973-385-4401

FAX: 973-385-3117

Customer No. 29668

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited
2/21/04 with the U.S. Postal Service
as first class mail under 37 C.F.R. 1.8 and is
addressed to the Assistant Commissioner for Patents,
Washington, D.C. 20231.

Christine Cicenia

Signature of Person Mailing Correspondence

Christine Cicenia

Typed or Printed Name of Person Mailing Certificate

Dated: 2/21/04

cc:



Docket No.: 020018-C2-03-DCL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Dennis Nelson and Craig Sheehan

Serial No.: 10/719,555

Group Art Unit: 1614

Filed: 11/21/2003

Examiner: Not yet assigned

For: Cyclodextrins In Dental Products

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. § 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449 submitted in accordance with 37 C.F.R. §§ 1.98 (a) (1) and 1.98 (b). It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein.

While no representation is made that any of these references may be "prior art" within the meaning of that term under 35 U.S.C. §§ 102 or 103, the enclosed list of references is disclosed so as to fully comply with the duty of disclosure set forth in 37 C.F.R. § 1.56.

Moreover, while no representation is made that a specific search of office files or patent office records has been conducted or that no better art exists, the undersigned attorney or agent of record believes that the enclosed art is the closest to the claimed invention (taken in its entirety) of which the undersigned is presently aware, and no art which is closer to the claimed invention (taken in its entirety) has been knowingly withheld.

In accordance with 37 C.F.R. § 1.98 (a) (2), unless otherwise indicated herein, a copy of each of the listed references or relevant portion thereof is also enclosed.

In accordance with 37 C.F.R. § 1.98(c), all English translations within the possession, custody, control or availability of anyone designated in 37 C.F.R. § 1.56(c) of each non-English reference, if any, are also enclosed.

The following are also included, if applicable, and as required under 37 C.F.R. § 1.98:

- In accordance with 37 C.F.R. § 1.98 (a) (3), the following concise explanation of the relevance of each listed reference that is not in the English language and is not accompanied by a translation into English or discussed in the present specification, is provided.
- The following listed references are not enclosed because, under 37 C.F.R. § 1.98 (c), they are substantially cumulative of the _____ reference:
- The following listed references are not enclosed because, under 37 C.F.R. § 1.98 (d), they were previously cited by or submitted to the Office in the _____ prior application, which is relied upon for an earlier filing date under 35 U.S.C. 120.

The certification specified in 37 C.F.R. § 1.97 (e), if required, is made below:


- I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97 (e) (1).
- I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56 (c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97 (e) (2).

Please credit any overpayment or charge any additional fees to Deposit Account No.:
23-0458.

Date:

2/2/04

Respectfully submitted,


Darryl C. Little
Reg. No. 40,703
Attorney For Applicant

Pfizer Inc.
201 Tabor Road
Morris Plains, NJ 07950
(973) 385-4401
FAX: (973) 385-3117
Customer No. 29668



Sheet 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF
(Rev. 2-32) COMMERCE
PATENT AND
TRADEMARK OFFICE
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
020018-C2-03-DCL	10/719,555
APPLICANT	
D. Nelson and C. Sheehan	
FILING DATE	GROUP
11/21/2003	1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6 2 6 1 5 4 0	7/01	Nelson	424	53	
	5 9 4 5 0 8 7	8/99	Nelson et al.	424	49	
	5 9 4 5 0 8 8	8/99	Delli Santi, et al.	424	49	
	6 5 3 4 0 4 2	3/03	Delli Santi, et al.	424	49	
	6 2 4 5 3 2 1	6/01	Nelson, et al.	424	49	
	6 2 3 5 2 6 7	5/01	Delli Santi, et al.	424	49	
	5 4 7 2 6 8 5	12/95	Galfar	424	49	
	5 6 2 6 8 3 7	5/97	Shimada, et al.	424	49	
	4 2 6 7 1 6 6	5/12/81	Yajima	424	48	
	4 7 2 7 0 6 4	2/23/88	Pitha	514	58	
	5 0 9 5 0 3 5	3/10/97	Eby, III	514	494	
	5 2 3 6 6 9 9	8/17/93	Libin	424	54	
	5 3 1 0 5 4 6	5/10/94	Douglas	424	53	
	5 3 5 6 6 1 5	10/94	Cai'far	424	49	
	5 3 8 2 5 6 7	01/95	Fuwa et al.	512	4	
	5 6 8 1 5 4 8	10/97	Esposito, et al.	424	49	
	5 7 2 3 1 0 6	03/98	Buch, et al.	424	49	
	5 3 3 0 7 4 9	7/94	Giacin, et al.	424	49	
	5 3 0 2 3 7 3	4/94	Giacin, et al.	424	49	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO
2 6 6 6 2 2 7	6/03/92	France (w/Abstract)			
9 4 1 6 6 7 4	8/4/94	PCT			
9 4 1 8 9 3 9	9/1/94	PCT			
9 5 0 3 7 0 9	2/9/95	PCT			
9 4 0 7 4 7 7	4/94	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)

Chemical Abstracts 120:37785
Chemical Abstracts 124:15302
Chemical Abstracts 107:161426
Chemical Abstracts 112:42263
Chemical Abstracts 17:157445
Chemical Abstracts 123:40750

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.